GSK3B Knockout HAP1 Polyclonal Cells provide a CRISPR/Cas9-mediated gene disruption of the GSK3B locus, generating a heterogeneous pool of edited near-haploid human cells. This polyclonal knockout population is designed for loss-of-function studies, enabling the investigation of GSK3B-dependent signaling networks without the confounding effects of compensated genetic redundancy. The cells serve as a robust tool for functional genomics, drug target validation, and pathway interrogation in a haploid genetic background.
The HAP1 cell line is a fibroblast-like, adherent cell model derived from the KBM-7 chronic myeloid leukemia line. Its near-haploid karyotype simplifies genetic analysis, as only one allele is present for most genes, facilitating the creation of clean knockout models. This characteristic reduces the complexity of gene editing and interpretation of phenotypic outcomes, making it particularly valuable for haploid genetic screens and systematic functional studies.
GSK3B encodes a constitutively active serine/threonine kinase that integrates signals from multiple pathways. Under basal conditions, GSK3B phosphorylates downstream targets including ??-catenin, glycogen synthase, c-Myc, cyclin D1, and tau, typically promoting their degradation or inhibiting their activity. Activation of Wnt signaling leads to the sequestration of GSK3B in a complex with AXIN1, APC, and Dishevelled, preventing ??-catenin phosphorylation and allowing its accumulation and TCF/LEF-mediated gene transcription. In insulin and growth factor signaling, AKT/PKB phosphorylates and inactivates GSK3B, relieving the inhibition of glycogen synthase and supporting cell survival and proliferation. GSK3B also interfaces with pathways such as Hedgehog and NF-??B, implicating it in a broad spectrum of cellular processes.
In the HAP1 near-haploid framework, disruption of GSK3B yields a clean loss-of-function model that circumvents interference from a second functional allele. This system is particularly suited to dissecting Wnt/??-catenin signaling, where the absence of GSK3B leads to constitutive ??-catenin stabilization and downstream transcriptional activation. Moreover, the haploid nature enhances the utility for drug sensitivity profiling, as compound effects can be directly attributed to target engagement without allelic compensation. The GSK3B knockout in HAP1 recapitulates key features of Wnt-driven oncogenesis and metabolic dysregulation, providing a platform for cancer research, Alzheimer??s disease modeling, and type 2 diabetes studies.
These cells are suitable for a variety of applications including haploid genetic screens, Wnt pathway dissection using TOPFlash reporter assays, insulin signaling studies monitored by phospho-AKT western blotting, and cell proliferation and apoptosis assays. Researchers can employ RT-qPCR to measure Wnt target gene expression (e.g., AXIN2, MYC), immunofluorescence to visualize ??-catenin localization, flow cytometry for cell cycle analysis, and glycogen synthase activity assays to assess metabolic outputs. The polyclonal pool also supports pooled CRISPR screening formats and serves as a reference for drug sensitivity profiling. For further details and customization options, contact Ascent Research.
